With Lilly's backing, a CRO with roots in China bags $150M round to fuel global growth
A renamed CRO with deep ties in the US and China has pulled in another round of capital.
ClinChoice, formerly Fountain Medical Development, has completed a $150 million Series E funding round, using the cash to continue its planned expansion.
According to ClinChoice CEO Ling Zhen, the funds from the round will be part of a two-pronged strategy centered around the company’s physical growth. One area will be going toward new solutions such as remote monitoring and data analytics but the other area will be toward a geographic expansion.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.